Funding

Seed funding
#Alzheimer's #Clinical trials #Drug discovery #Funding

€9 million to address ‘Agitation/Aggression’ in Alzheimer’s

Exciva has closed a Series A financing of €9 million, led by Andera Partners, to develop the lead compound up to completion of Phase I. The product has the potential to treat behavioral and psychological symptoms in Alzheimer disease patients. This compound is the combination of two clinically validated products,… Read More

#News

#Cancer #Cancer research #Clinical trials #Funding

Leucid Bio raises £11.5 million to develop CAR-T cell therapies 

Leucid Biohas raised £11.5 million in a Series A financing round, which will be used to initiate a Phase I trial of its lead candidate, LEU-011, for the treatment of platinum resistant ovarian cancer.  CAR T-cell therapy is a technology in which the patient’s own immune cells are reprogrammed… Read More

#News

#Collaboration #Drug discovery #Funding #Research

This week in drug discovery (18-22 October) 

News round-up by DDW’s Megan Thomas for 18-22 October  DDW’s Megan Thomas has selected five stories which highlight the opportunities in the drug discovery sector.   1. Researchers receive $4 million for exceptional junior scientists  Two Mount Sinai cancer researchers will receive $4… Read More

#News

#Chronic pain #Funding #Lab automation #Lead optimisation

NIH grant for discovery of novel non-opioid drugs for chronic pain 

1910 Genetics has been awarded an approximate $550,000 Phase I STTR grant by the National Institutes of Health (NIH).   The grant, received from the National Institute of Neurological Disorders and Stroke (NINDS) as part of the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, supports… Read More

#News

#Cancer immunotherapy #Funding #Immunology #Precision medicine #Tumour biology

Researchers receive $4 million for exceptional junior scientists

Two Mount Sinai cancer researchers will receive $4 million from the National Institutes of Health (NIH) Common Fund, which supports research by junior scientists around the United States. This will fund radiation oncology and CAR T cell cancer therapy research.  Deborah Marshall, Assistant Professor of Radiation Oncology at The Tisch… Read More

#News

#Data science #Funding #Pharmaceuticals

€1.3 million seed round to shift pharmaceutical dealmaking online

Pipelinepharma, a European B2B pharmaceutical marketplace, closed a venture seed round led by Practica Capital. The marketplace has facilitated pharmaceutical product licensing, supply, acquisition deals of more than €200 million in value, covering more than 30 markets on five continents. The investment will help attract talent to… Read More

#News

#Funding #Immunology / Virology & Vaccines #mRNA

£4 million funding raised for rapid vaccine development platform  

Imophoron, the Bristol-based developer of a rapid-response vaccine platform, ADDomer, has secured £4 million in an oversubscribed fundraising round. Frederic Garzoni, CEO and Co-founder of Imophoron, said: “It has now been demonstrated how a pandemic cannot just threaten lives, but our society and economy as we know it. Imophoron is developing its ADDomer vaccine platform… Read More

#News

#Clinical trials #Covid-19 #Funding

iiCON secures over £150 million investment and creates 176 jobs   

The Infection Innovation Consortium (iiCON) is a global centre for infectious disease R&D and created 176 high-value jobs in the North West of the UK.   The consortium has raised £154.9 million in public and private investment in its first year – creating a £173.5 million programme. … Read More

#News

Seed funding
#Clinical trials #Covid-19 #Drug discovery #Funding #Research #Therapeutics

ILC Therapeutics completes £3.5 million funding round 

ILC Therapeutics has completed a £3.5 million pre-IPO funding round. Investors include Robert Kopple, Eos Angel Investment Syndicate, Scottish Enterprise and ILCT management.  Chairman Peter Bains said: “With this funding in place, ILCT is now well positioned to strengthen its novel technology platform and to advance its lead candidate, Alfacyte… Read More

#Business & Investment #News

#Biotherapeutics #Collaboration #Funding #HIV #Pharma

This week in drug discovery (16-20 August) 

News round-up by DDW’s Megan Thomas for 16-20 August  DDW’s Megan Thomas selects five news stories which spotlight the deals, collaborations and funding keeping the industry moving forward, enabling academics and drug developers to continue with life-saving research.   1. OGT training initiative with CytoCell University … Read More

#News #Trending News

#CRISPR #Drug discovery #Funding #Gene editing #HIV #Research

NIH invests $53 million in HIV cure research  

The National Institutes of Health (NIH) has awarded approximately $53 million in annual funding over the next five years to ten research organisations in a continued effort to find a cure for HIV.   The new awards for the Martin Delaney Collaboratories for HIV Cure Research programme expand the initiative’s 2016 renewal from six institutions to ten. Read More

#Business & Investment #News

#Funding #Rare disease #Therapeutics

Angelini Pharma and Lumira Ventures launch the ALBF

Angelini Pharma and Lumira have launched the Angelini Lumira Biosciences Fund (ALBF), which has been established to invest in early-stage companies in Canada and U.S. markets that are developing pharmaceutical therapies for central nervous system disorders (CNS) and rare diseases. The ALBF will be managed by Lumira Ventures and Angelini… Read More

#News #Start-up Zone

#Drug development #Funding #Mental health

Funding completed to develop psychedelic medicine breakthroughs

Beckley Psytech has completed Series B financing, raising $80 million from venture capital (VC) investors to fund its research programmes. The financing was initially set at $50 million and was upsized to $80 million due to interest from investors in broadening and accelerating the clinical development of Beckley Psytech’s research… Read More

#News

#Alzheimer's #Drug development #Funding #Research

NIH awards $15 million for Alzheimer’s research

The National Institute of Aging (NIA), part of the National Institutes of Health, has awarded Wake Forest School of Medicine $15.2 million over five years in support of its research centre for Alzheimer’s disease. Established in 2016 with a multimillion-dollar NIA grant, the Alzheimer’s Disease Research Center (ADRC) at Wake… Read More

#News #Trending News

#Clinical trials #Covid-19 #Data #Funding #Therapeutics

Appili Therapeutics secures $3.5 million in funding

Appili Therapeutics has entered into a $3.5 million convertible security funding agreement with Lind Global Fund. The company intends to use the funding to advance the broader Appili pipeline, including ATI-2307, a novel clinical stage antifungal expected to enter Phase II study in 2022. It will also support the operations… Read More

#News

#Drug development #Drug innovation #Funding #Research #Therapeutics

Orbit Discovery plans growth in peptide discovery business

Orbit Discovery has raised US$7.6 million which will be used to accelerate its growth as a provider of peptide discovery services to the biotechnology and pharmaceutical industry. Orbit Discovery’s novel bead-based and microfluidic technology platform enables the screening of peptide libraries for target binding and subsequent activity in cell-based functional… Read More

#News